文献速递乳腺癌支持与姑息治疗

实体瘤中肿瘤浸润性克隆性造血与泛癌预后

Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors.
PubMed 文献 · JAMA Oncol · 2026-01-01

TI-CH与更差的泛癌总生存显著相关,其中GATA2变异与泛癌生存更差相关,TET2变异与乳腺癌生存更差相关。

要点

  • 实体瘤中TI-CH检出率为18.38%,子宫内膜癌频率最高(32%)。
  • TI-CH与更差泛癌OS显著相关(HR 1.13),乳腺癌OS关联更强(HR 1.95)。
  • GATA2变异与泛癌OS更差相关,TET2变异与乳腺癌OS更差相关。

核心结论

  • 在实体瘤患者中,TI-CH与更差的总生存显著相关,提示其可能作为预后生物标志物。

主要发现

  • TI-CH与年龄增长(OR 1.15,95%CI 1.10-1.19)和细胞毒性化疗(OR 1.24,95%CI 1.06-1.44)相关。
  • TI-CH与更差泛癌OS显著相关(HR 1.13,95%CI 1.02-1.25),乳腺癌OS关联更强(HR 1.95,95%CI 1.54-2.48)。
  • GATA2变异与更差泛癌OS显著相关(HR 3.00,95%CI 1.61-5.59)。
  • TET2变异与更差乳腺癌OS显著相关(HR 2.92,95%CI 1.59-5.37)。

关键数值与推荐

  • TI-CH定义为肿瘤组织中74个驱动基因的体细胞变异,变异等位基因频率2%至30%。

临床怎么用

  • TI-CH检测或可辅助实体瘤预后分层,尤其乳腺癌中TET2变异和泛癌中GATA2变异值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tumor-infiltrating clonal hematopoiesis (TI-CH) indicates the infiltration of somatically mutated hematopoietic cells into the tumor microenvironment. While clonal hematopoiesis is a known prognostic factor in hematologic malignant neoplasms, the clinical relevance of TI-CH in solid tumors remains poorly understood. OBJECTIVE: To characterize the prevalence of TI-CH in solid tumors and evaluate its association with clinical factors and overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed whole-genome sequencing data of a large cohort of patients with solid tumors from the Genomics England 100 000 Genomes Project between 2015 and 2019. The data analysis was conducted from June to November 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was the prevalence of TI-CH, defined by somatic variants in 74 driver genes (variant allele frequency 2% to 30%) in tumor tissue. Secondary outcomes included associations of TI-CH with clinical factors (age, cytotoxic chemotherapy) and OS, assessed using Cox proportional hazards models. RESULTS: Among 10 571 patients with solid tumors (mean [SD] age, 64.68 [12.18] years; 6430 [60.83%] female), TI-CH was detected in 1943 patients (18.38%), with the highest frequency observed in patients with TET2 variants (212 patients [10.91%]) and in patients with endometrial cancer (251 patients [32%]). TI-CH was more common with older age (odds ratio [OR], 1.15 [95% CI, 1.10-1.19]) and cytotoxic chemotherapy (OR, 1.24 [95% CI, 1.06-1.44]). TI-CH was significantly associated with worse pan-cancer OS (hazard ratio [HR], 1.13 [95% CI, 1.02-1.25]), particularly breast cancer OS (HR, 1.95 [95% CI, 1.54-2.48]). At the gene level, worse pan-cancer OS was significantly associated with GATA2 variants (HR, 3.00 [95% CI, 1.61-5.59]), and worse breast cancer OS was significantly associated with TET2 variants (HR, 2.92 [95% CI, 1.59-5.37]). CONCLUSIONS AND RELEVANCE: In this cohort study, older age and cytotoxic chemotherapy were associated with higher odds of TI-CH. TI-CH was associated with worse survival in patients with solid tumors, specifically implicating GATA2 (pan-cancers) and TET2 (breast cancer) variants. These findings suggest TI-CH may serve as a prognostic biomarker in patients with solid tumors.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yun D, Chen C, Qin N, et al. Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors. JAMA Oncol. 2026. PMID: 42096237. doi:10.1001/jamaoncol.2026.1036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。